Refusal of Sentinel Lymph Node Biopsy in Patients With Luminal A Subtype Early Breast Cancer

Sentinel lymph node biopsy (SLNB) is the standard of axillary lymph node surgical staging in patients with early breast cancer. The main goal of the study is to abandon axillary surgery in patients over 59 years old with early, luminal A, clinical lymph node negative breast cancer.

Trial Details

NCT ID
NCT07579286
Phase
NA
Sponsor
N.N. Petrov National Medical Research Center of Oncology
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • breast resection
  • Breast resection with sentinel lymph node biopsy
Locations (sample)
  • Saint Petersburg, Russian Federation, Russia|59.93863,30.31413

Key Eligibility Criteria

  • HER2-negative breast cancer (ER +/ PR +), Ki67 \<= 30%, G1-2
  • age\> 59 years.
  • morphologically confirmed diagnosis of breast cancer, IA-IIA stage
  • ECOG score 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →